November 17, 2020 – AVROBIO announced that data suggests functional and clinical improvements for the first cystinosis patient at 1 year. A new patient has been dosed this month in the investigator-sponsored study of AVR-RD-04 for cystinosis, marking the halfway point for enrollment with three patients dosed in total. More information is available here.